A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

September 30, 2016

Conditions

Advanced CancerMetastatic Solid Tumors

Interventions

DRUG

NKTR-102

Trial Locations (3)

University Hospitals Case-Medical Center Seidman Cancer Center, Cleveland

American Institute of Research, Los Angeles, Los Angeles

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco